Objective: To determine whether changing antiretroviral therapy (ART) during pregnancy because of concern about fetal risks led to poorer virological outcomes.
INTRODUCTION
One of the major benefits of antiretroviral therapy (ART) is to prevent perinatal transmission, [1] [2] [3] [4] [5] [6] [7] [8] [9] attaining zero transmission when maternal viral load is undetectable from conception until delivery. 10 Because lifelong ART is recommended for all people living with HIV, 5 women are increasingly on treatment at the time of conception. Thus, safety issues are of crucial importance to choose which antiretrovirals to use in pregnancy. A variety of adverse events have been reported to be related to antiretroviral exposure during pregnancy, regarding the fetus and future infant, the woman herself, and pregnancy outcomes. [11] [12] [13] [14] [15] [16] [17] [18] For women taking medications who become, or plan to become pregnant, clinicians and patients are faced with a choice of whether or not it should be changed for safety concerns, even in the absence of intolerance or inefficacy. Recommendations are periodically updated according to the available data and interpretation of benefits and risks. [2] [3] [4] [5] [6] Expert panels diverge about how to take into account pregnancy-specific safety issues, for several reasons. First, there is debate over the actual risks, for instance, whether exposure to efavirenz increases the fetal malformation rate. 15, 19 Second, there is debate as to whether recent medications should be avoided in pregnancy as long as safety data are lacking. Third, there is concern that switching may lead to poorer compliance or tolerance and thus virological failure, which is the main risk factor for perinatal transmission. 20, 21 In France, as in many other countries, boosted protease inhibitors (PIs) associated with 2 nucleoside reverse transcriptase inhibitors (NRTIs) have been the first-line therapies for pregnant women for 2 decades, whereas WHO guidelines favor efavirenz with 2 NRTIs. 22 French guidelines 23 suggest that even in case of virological efficacy, consideration should be given to changing an ART in case of concern about potential safety risks. In many other countries, it is recommended not to change an effective treatment during pregnancy. 24, 25 However, following a recent report of an increased incidence of neural tube defects associated with dolutegravir use, 26 several guidelines recommended switching from dolutegravir to other drugs in the periconceptional period. [27] [28] [29] The objective of our study was to determine whether changing ART in pregnant women who were on effective therapy at conception had an impact on viral load and pregnancy outcomes.
METHODS

The French Perinatal Cohort
The French Perinatal Cohort (ANRS EPF CO1/CO11) is a prospective, observational study ongoing since 1985 in 90 perinatal centers throughout France, 7 which includes all pregnancies in women with HIV-1 and/or HIV-2 with their informed consent and ethics committee (Comité de Protection des Personnes) approval. Clinicians record maternal and obstetrical data and follow-up of the infant until 2 years of age if not infected or 18 years if HIV-infected. EPF coverage is estimated at 70% of pregnancies of HIV-positive women in France. The cohort comprised 2 components, CO1 and CO11. More detailed data are collected in the CO1 component performed in selected study sites.
Study Population
For the current analysis, we included all pregnancies in EPF CO01, for which the outcome occurred at 14 week gestation (WG) or more, from January 1, 2005, to December 31, 2015. We selected only women who were already on antiretroviral therapy at the time of conception and had a HIV-1 plasma viral load available before 14 week gestation (WG), which was ,50 copies/mL. Women with HIV type 2, for whom the recommendations are different, were excluded (N = 188).
Exposure
All treatment regimens were collected with the initiation and end dates for each drug. We defined a treatment switch as the change of at least one drug, that is, the addition, modification, or deletion of a drug in the combination of treatments present at conception. Changes in dose, as well as treatment interruptions, were not considered as switches. The type of treatment at conception was classified into 3 categories: recommended as first-line during the pregnancy, alternative, and not recommended (NR) in the first trimester of pregnancy, according to the French national guidelines at the time of conception for each pregnancy. [2] [3] [4] [5] [6] In the category of "NR" treatments, we included both contraindicated treatments and those with insufficient data in pregnancy to recommend. This classification was made considering for each treatment regimen the individual drugs and their combinations during the pregnancy (see Table A Efavirenz was not recommended throughout the study period, as were the other NNRTIs, except for nevirapine started before conception. The integrase inhibitors (raltegravir and dolutegravir) were all in the NR group until the most recent guidelines. For NRTIs, tenofovir was in the insufficient data group until 2011, and throughout the study period, it was recommended not to use solely NRTIs, whether monotherapy, double therapy, or a triple NRTI regimen.
We also studied treatment changes beyond the first trimester, whether or not the ART regimen was switched in the first trimester.
Outcomes
We studied the characteristics potentially associated with treatment change, ie, sociodemographic and behavioral characteristics of the mother, clinical and obstetrical factors, HIV infection characteristics, and the antiretroviral therapy history.
We studied outcomes following switches in the first trimester of pregnancy (,14 WG). The main outcome was maternal viral load nearest to the time of delivery and also during the pregnancy to study the first occurrence of a value above a cutoff of 50 copies/mL. 30 Other pregnancy outcomes studied were the mode of delivery, preterm delivery (,37 WG), and adverse outcomes defined as neonatal deaths, terminations of pregnancy, or in uterofetal demise. Infant outcomes studied were HIV transmission and mortality before 1 year of age.
Statistical Analysis
The main analysis was restricted to first-trimester changes for safety concerns in HIV-1-infected patients on ART at conception with viral suppression documented by a viral load ,50 copies/mL before 14 WG, after exclusion of changes for inefficacy (N = 23) or intolerance (N = 22) (EPF CO1, N = 1780). We examined the factors potentially associated with a change in treatment before 14 week gestation. For this, we performed x 2 or Fisher exact test and logistic regressions. Multivariate models were developed by including the noncollinear variables found associated with univariate P ,20% after looking for potential interactions. A propensity score was calculated, defined by the probability of early change for safety concerns as a function of the initial characteristics, estimated by the final logistic regression model. To construct this score, we used the variables significantly associated with the probability of changing treatment after eliminating potential colinearities and interaction. Verification steps (analysis of the standardized differences and the disappearance of the association between each variable independently with the change after adjustment on this score 31 ) were performed to verify the good performance of the propensity score.
Finally, we studied the association between 1st trimester changes for safety concerns and virological control, complications of pregnancy, and neonatal outcomes. For this purpose, we performed univariate and multivariate analysis, using logistic regressions for delivery outcomes or Cox models for outcomes occurring during pregnancy. In case of additional treatment changes, time for survival analysis was censored at the date of the second change. We performed additional subgroup analyses according to the treatment recommendations: recommended, alternative, or NR.
Multivariate analysis was performed with adjustment for the propensity score and factors found to be associated with outcomes in the univariate analysis at P level of 0.20. To account for the effect of enrolling woman more than once for successive pregnancies, we adjusted our analyses on the number of previous pregnancies in the cohort.
All analyses were performed using STATA 14 software.
RESULTS
Of a total of 10,553 pregnancies in HIV-1-infected women with an outcome $ 14 WG included in the EPF cohort between 2005 and 2015, 7079 were included in the more detailed component of the cohort (EFP CO01), which collects data from conception to delivery ( Fig. 1 . Flow chart), one half of whom (N = 3574) were on antiretroviral therapy at conception.
Overall, there was a treatment change before 14 WG because of safety concerns in 411 (23.2%) of the 1775 women who were on antiretroviral therapy at conception and had a viral load , 50 copies/mL in the first trimester and no documented intolerance.
Factors Associated With Changes
Among women with a viral load , 50 copies/mL in the first trimester who changed solely for safety concerns (N = 411), as expected, the incidence of ART switch was higher when their regimen was NR (not recommended) or A (alternative) compared with those receiving R (recommended) first-line treatment [48.7% (315/647), 9.9% (71/720), and 6.1% (25/408), respectively; P , 0.01]. Other factors associated with an ART switch were younger maternal age, increasing time between HIV diagnosis and pregnancy, being single versus married/cohabiting, unemployed versus employed/studying, birth in sub-Saharan Africa, primiparity, living in the Paris area, and a low CD4 count. Changing for safety concerns was not significantly associated with the timing of the first prenatal (booking) visit, the level of neonatal care in the institution, BMI, tobacco use or alcohol use, singleton versus twin pregnancy, mode of HIV acquisition, or assisted reproduction versus spontaneous conception (Tables 1 and 2 ).
In the multivariate analysis, ART changes for safety concerns remained significantly associated with the type of treatment according to guidelines; adjusted ORs were 2.2 [1. 3-3.7] for alternate ARTs and 23.1 [14.0-38.2] for NR ARTs, versus first-line therapy; P , 0.01 (Table 3) . The geographical region, delivery period, marital status, time since HIV diagnosis, and number of previous pregnancies enrolled in the EPF cohort remained significantly associated with the probability of first-trimester treatment switching for safety concerns.
We established a propensity score for each patient from the final multivariate model to study association between ART change for safety concerns and virological and pregnancy outcomes (Table 3 ). The variables retained in the final model for the propensity score were the number of previous pregnancies in the cohort, geographical region, delivery period, marital status, and time since HIV diagnosis.
Impact of ART Switch on Viral Load and Pregnancy Outcomes
In women with viral suppression on ART at conception, changing ART in the first trimester for safety concerns was not associated with the time to virological rebound during pregnancy [Kaplan-Meier estimates: 19.3% in the switch group vs. 15.6%, HRa: 1.0 (0.7-1.4)], nor was it associated with the incidence of virological rebound, defined as a plasma viral load .50 copies/mL near delivery: 6.5% versus 4.6% ORa: 1.1 (0.6-2.0) ( Table 4) .
First-trimester ART changes were not associated with any adverse pregnancy outcomes (1.9% vs. 2.9%), mode of delivery, perinatal deaths, or HIV transmission to the child (Table 4) .
The proportion of ART changes for any reason beyond 14 WG tended to be higher in women who had a first-trimester switch for safety concerns than in women who did not switch (23.1% vs. 14.0%), but the difference was not statistically significant (P = 0.4); the reasons for these changes did not differ between groups (P = 0.9). The reasons for subsequent changes in women with a first-trimester switch for safety concerns were intolerance in 30.6%, virological rebound in 25.8%, and other pregnancy-related concerns in 43.6%. The respective proportions for those who had no first-trimester switch for safety concerns were, respectively, 36%, 20%, and 44%.
In subgroup analyses, virological rebound was not associated with early change for safety concerns when the initial regimen was not recommended (see Table B , Supplemental Digital Content, http://links.lww.com/QAI/B271). When the initial regimen was considered as an alternative treatment, the proportion of virological rebound tended to be higher following changes for safety concerns [27.5% vs. 14.3%, HRa: 1.6 (0.9-2.9)], although the difference was not statistically significant (P = 0.2). We performed the same analyses for women on efavirenz who had a first-trimester switch, in line with French guidelines throughout the study period. There was no significant difference in the proportion of VL . 50 copies/ mL [16.8% in 143 pregnancies with a first-trimester switch from efavirenz vs. 15.6% in the overall group of 1364 pregnancies without a first-trimester switch, HRa: 1.1 (0.7-1.8), P = 0.7] (see Table C , Supplemental Digital Content, http://links.lww.com/QAI/B271). 
DISCUSSION
Our findings are reassuring regarding the decision to change antiretroviral therapy in early pregnancy to avoid exposure to medications with potential fetal risks. There was no increase in virological rebound above 50 copies/mL, compared with pregnancies in which the initial ART regimen was maintained. In all cases, the ART regimen could be changed again later in pregnancy in case of poor tolerance or inefficacy. Of concern, whatever the treatment group, the proportion of women who failed to maintain viral suppression throughout their pregnancy was on the average 15.6%. The proportion is, however, much lower than in some other highresource settings. 32 The incidence of virological rebound in all groups was quite similar to that reported in the nonpregnancy literature. [33] [34] [35] By contrast, Floridia et al 36 previously reported that women who had a treatment change in pregnancy were almost twice as likely to have a viral load higher than 400 copies/mL at the end of pregnancy compared to women with no such changes. However, the design of the study differed from ours because it included switches for toxicity or failure/ resistance, patients who were not on ARV at the time of conception or with baseline viral loads above 400 copies/mL accounting for more than one-half of the population, as well as ARV switches in the second and third trimester. Nevertheless, as previously reported in the Italian cohort, 37 treatment interruptions during the first trimester, which were common at the time of the study in 2001-2008, were not associated with an increased incidence of detectable viral load before delivery.
In our cohort, the overall proportion of ART switches during pregnancy was 35%, of which more than one-half occurred in the first trimester, comparable with findings from a British study conducted in an earlier period. 38 The main reason for switching ART in the first trimester was to conform to the guidelines. Women were 23 times more likely to switch ART if it was not recommended, but decisions regarding ART regimens classified as alternative were less clear-cut, with a 2-fold increase in first-trimester ART switches, reflecting uncertainty about risks/benefits. In a small group of pregnancies, a first-line regimen was changed despite recorded efficacy and no reported intolerance; the reasons were not available. Efavirenz-based ART was singled out in French guidelines, as well as in US guidelines until recently, as requiring a first-trimester switch, whereas other guidelines recommended it throughout pregnancy. 22, 25, 39 We did not observe a higher proportion of viral load rebound in women who changed from efavirenz. Nevertheless, nearly one-half of women with ART regimens that were not recommended at the time maintained their therapy in the first trimester. This may be due to previous resistance or tolerance issues, differences in the frequency and timing of clinic visits for HIV care, lack of knowledge regarding the latest pregnancy guidelines among some clinicians, and concern about jeopardizing treatment compliance. Treatment switches were less frequent for women who had a longer time since their HIV diagnosis, possibly in view of their treatment history limiting the therapeutic options. It is interesting to note that among women with NR regimens who did not switch in the first trimester, a high proportion ended up switching later in the pregnancy.
In our analysis, markers of social and personal vulnerability or deprivation were associated with changes in ART regimen later in pregnancy, which may reflect poorer engagement in care including family planning and treatment adaptation before conception.
This highlights the need for multidisciplinary care, particularly preconceptionally, to choose an ART regimen taking into account the desire for pregnancy with an optimal control of viral load, adherence, and tolerance, in view of the benefits/risks for the pregnancy as well as for the woman's long-term health and to avoid HIV transmission to the partner. 40 The main strengths of this study are the large, multicenter enrollment and the prospective collection of detailed data, especially regarding the reasons for treatment change. Also, we carefully classified antiretroviral prescriptions and changes with regard to successive changes in guidelines. We chose to perform some of the survival analyses to account for the delay between first-trimester change and the possible occurrence of a complication or subsequent changes in ART because the gestational age may have an influence on the decisions as well as later outcomes. The observational design is a limitation of our study, which is only partially offset by use of a propensity score. The main limitation is the extent to which our results concerning French recommendations and practices are applicable in resourcelimited settings, where close follow-up and viral load monitoring are not available.
In the decade we studied, the principal ART regimens that were discouraged in the French guidelines were efavirenz and triple NRTIs, as well as several antiretrovirals which are no longer in use, for instance, didanosine and stavudine. We defined a change in ART to include any addition, deletion, or change of at least one drug in the combination. Today, the main issue is whether to switch from single-tablet regimens without pregnancy safety data to regimens with several tablets or administered twice a day. Because efavirenz-based therapy was usually a single-tablet regimen, switching to a boosted PI-based regimen meant increasing the pill burden, and this did not lead to poorer virological outcomes. Some studies 41, 42 have found that compliance is improved during pregnancy, which may suggest that women are willing to make special efforts to improve their chance of having a healthy child.
When recommending the avoidance of certain antiretrovirals, a fundamental issue is whether the potential risks justify this precaution. For most recent medications, there is simply not enough pregnancy data to conclude about their safety. Few antiretrovirals have documented risks for the fetus. Regarding efavirenz, preclinical primate data showed an increased risk of neural tube defects, and an increased incidence of malformations was reported after first-trimester exposure in some clinical studies including the French cohort. 15 This led the French expert panel to discourage efavirenz in the first trimester of pregnancy, whereas WHO guidelines 22 recommended efavirenz in pregnant women, based on reassuring data from other sources. 43 .Although the safety of efavirenz now seems to be confirmed, 26 the recent alert concerning dolutegravir 26, 27 is an illustration of the potential risk of treating pregnant women with medications that have not yet been evaluated for safety in pregnancy. In case of such controversy, approaches may differ between expert guidelines because of different analyses of the benefits and risks according to the populations, health systems, and resources.
CONCLUSIONS
Changing antiretroviral therapy early during pregnancy with the goal of improving fetal and pregnancy outcomes did not seem to have a destabilizing effect on viral suppression. To avoid exposing the fetus to potentially harmful medications, multidisciplinary care and discussion with each woman should be encouraged, and the optimal treatment regimen should be chosen preconceptionally. As guidelines evolve, it is also important to inform clinicians. Since a large number of effective antiretroviral regimens are now available, the choice of which ones to use requires adequate data on their risks. This requires ongoing research, including follow-up in cohort studies and randomized controlled trials.
